Dec 13, 2019 / 05:00PM GMT
John L. Lubniewski - HTG Molecular Diagnostics, Inc. - President, CEO & Director
I think we're going to start up the session. So good afternoon. I'd like to welcome everyone here and those on the webcast. My name is John Lubniewski, I'm the President and the CEO of HTG Molecular Diagnostics. I'm joined by my colleagues, Byron Lawson upfront; and Shaun McMeans, our Chief Financial Officer in the back; and also by our special guest today, Dr. Laura Benjamin from Oncologie.
Our program is as follows: Byron is going to walk you through a brief overview of HTG and our overall business and provide details on our pharma partnership programs, including an exciting new advancement in our technology. Byron will then introduce Dr. Benjamin, who will present her perspectives on the challenges of bringing innovative new medicines to patients in the era of biomarkers. And then last, we'll open the floor to questions, both to the HTG management team as well as to Dr. Benjamin.
Before I let Byron get started, I just want to remind everyone of the forward-looking statements.
And with that,
HTG Molecular Diagnostics, Inc. - Special Call Transcript
Feb 13, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers